EUVIMEDEUVIMED entdecken
Open Access

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide

Elizabeth Nettleton iD, Sebastian E Sattui iD, Zachary Wallace, Michael Putman

Arthritis Care & Research · 2024-02 · 76 (2) · 288-294

DOI: 10.1002/acr.25222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 28.10.2023. Verfasst von Elizabeth Nettleton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, Wisconsin. Hauptthemen laut MEDLINE: Pneumocystis carinii, Pneumonia, Pneumocystis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This manuscript assesses the incidence of Pneumocystis jiroveci pneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and adverse events associated with PJP prophylaxis.

Methods

Incident users of rituximab or cyclophosphamide for AAV were identified in the TriNetX electronic health records database from 2011 to 2022. The incidence rates (IRs) of PJP in the first 6 months of induction therapy with rituximab and/or cyclophosphamide and during postinduction maintenance therapy with rituximab were calculated. Cox proportional hazard models were used to estimate hazard ratios (HRs) and confidence intervals (CIs) for the risk of adverse events commonly associated with PJP prophylaxis.

Results

We identified 1,461 AAV cases who received induction therapy with rituximab (69.7%), cyclophosphamide (18.9%), or both (11.4%). Prophylaxis prescribed within 30 days of induction included trimethoprim‐sulfamethoxazole (30.7%), atovaquone (5.4%), dapsone (3.8%), and pentamidine (0.8%). During induction therapy, 10 cases of PJP were identified (IR 15.0 cases per 1,000 patient‐years); no deaths occurred. In adjusted analyses, those who received prophylaxis had a higher risk of leukopenia (HR 3.1; 95% CI 1.1–8.6), rash (HR 1.9; 95% CI 1.0–3.6), and nephropathy (HR 2.6; 95% CI 1.3–5.1) than those who did not. During rituximab maintenance therapy (n = 709), five cases of PJP were identified (IR 2.1 cases per 1,000 person‐years), one of whom died during the hospitalization associated with a PJP diagnosis.

Conclusion

Rates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumocystis cariniiPneumonia, PneumocystisAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansRituximabIncidenceCyclophosphamide

Substanzen

RituximabCyclophosphamide

Autor:innen und Institutionen

  • Medical College of Wisconsin, Milwaukee, Wisconsin.
  • University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Harvard Medical School, Boston, Massachusetts.

ORCID-Profile: Elizabeth Nettleton, Sebastian E Sattui

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Rheumatology Research Foundation

Zitieren

APA

Nettleton, E., Sattui, S. E., Wallace, Z., & Putman, M. (2024). Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care & Research, 76(2), 288-294. https://doi.org/10.1002/acr.25222

Vancouver

Nettleton E, Sattui SE, Wallace Z, Putman M. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care & Research. 2024;76(2):288-294. doi:10.1002/acr.25222

BibTeX
@article{Nettleton2024,
  author = {Nettleton, Elizabeth and Sattui, Sebastian E and Wallace, Zachary and Putman, Michael},
  title = {Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide},
  journal = {Arthritis Care & Research},
  year = {2024},
  volume = {76},
  number = {2},
  pages = {288--294},
  doi = {10.1002/acr.25222}
}
Kostenlos starten →